AntibioticDB

Teicoplanin

Glycopeptide

Sanofi-Aventis, FR

1989

Highest development stage: Phase 4
Gram-positive activity
Mechanism of Action/Target pathogen: Inhibits cell wall biosynthesis by binding Lipid II. Used in the treat of serious Gram-Postive infections, including MRSA and E.faecalis
GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10924
Source: https://www.nature.com/articles/s41429-020-0313-6
Citation (1): https://link.springer.com/article/10.1007/BF01967563
Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/133065662